Can hormone replacement therapy (HRT) in postmenopausal women increase blood pressure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Postmenopausal HRT Increase Blood Pressure?

Yes, postmenopausal HRT can modestly increase blood pressure, but the effect depends critically on the formulation used—oral conjugated equine estrogens (CEE) with progestogen increase systolic blood pressure and hypertension risk, while transdermal estradiol-based regimens appear neutral or may even reduce blood pressure.

Evidence-Based Breakdown by Formulation

Oral Conjugated Equine Estrogens (CEE) + Progestogen

The largest and highest quality evidence comes from the Women's Health Initiative (WHI), which found 1:

  • Average 1 mm Hg increase in systolic blood pressure over 5.6 years in 8,506 women using CEE plus medroxyprogesterone acetate
  • 25% greater likelihood of developing hypertension compared to non-users in cross-sectional analysis of nearly 100,000 women
  • No significant effect on diastolic blood pressure

A 2024 meta-analysis confirms this, showing oral CEE plus progestogen specifically increases systolic blood pressure (SMD = 0.60 mm Hg) 2. An Australian cohort study of 43,405 women demonstrated increased odds of hypertension with past MHT use, with effects strongest in younger postmenopausal women and increasing with duration of use 3.

Transdermal Estradiol ± Progestogen

The evidence strongly favors transdermal preparations 2, 4, 5, 6:

  • No significant blood pressure increase with transdermal estradiol plus progestogen (SMD = -2.00 mm Hg, 95% CI = -7.26 to 3.27)
  • Multiple 24-hour ambulatory blood pressure studies show blood pressure reductions in 11 of 13 studies using transdermal estradiol
  • One study of 1,397 hypertensive women using transdermal HRT showed average reductions of 7 mm Hg systolic and 9 mm Hg diastolic 4

Oral Estradiol-Based Regimens

Oral estradiol (not CEE) plus progestogen, estradiol alone, and tibolone showed no significant blood pressure effects 2, 5.

Clinical Algorithm for HRT and Blood Pressure Management

For normotensive women considering HRT:

  • Prefer transdermal estradiol-based preparations over oral CEE formulations
  • Monitor blood pressure closely at initiation, then at 6-month intervals 1

For hypertensive women considering HRT:

  • Transdermal estradiol is the preferred formulation given neutral-to-beneficial blood pressure effects 4, 5, 6
  • Oral CEE formulations should be avoided due to increased hypertension risk
  • Blood pressure should be monitored closely at first, then at 6-month intervals 1
  • Among progestins, drospirenone (spironolactone-derived) has the best antihypertensive properties 6

For women already on oral CEE-based HRT:

  • Monitor blood pressure every 6 months
  • Consider switching to transdermal estradiol if blood pressure increases
  • Discontinuation may actually increase hypertension risk in some women 7

Important Caveats

The Formulation Matters More Than "HRT" as a Class

The JNC-7 guidelines appropriately conclude that "HRT-related change in BP is likely to be modest and should not preclude hormone use in normotensive or hypertensive women" 1. However, this statement predates the 2024 meta-analysis showing clear differences between formulations 2. The type of estrogen (CEE vs. estradiol) and route of administration (oral vs. transdermal) are critical determinants of blood pressure effects.

Conflicting Evidence Explained

Smaller observational studies (Baltimore Longitudinal Study on Aging, Postmenopausal Estrogen/Progestin Intervention trial) showed either beneficial or neutral effects 1, 8. These discrepancies likely reflect:

  • Different formulations studied (many used estradiol rather than CEE)
  • Selection bias in observational studies
  • The WHI remains the gold standard with its large randomized design

The Effect is Modest but Clinically Relevant

While the absolute blood pressure increase with oral CEE is small (1 mm Hg systolic), the 25% increased likelihood of developing hypertension is clinically significant given hypertension's impact on cardiovascular morbidity and mortality 1.

Potential Benefits on Circadian Blood Pressure

Some studies suggest HRT may restore normal nighttime blood pressure "dipping" that diminishes in postmenopausal women, potentially reducing target organ damage despite modest daytime increases 1. However, this benefit appears more consistent with transdermal preparations.

Bottom line: Hypertension should not be considered an absolute contraindication to HRT, but formulation selection matters—choose transdermal estradiol-based regimens for hypertensive women and monitor blood pressure regularly regardless of formulation used.

Related Questions

In a 65-year-old woman with uncontrolled hypertension, should hormone replacement therapy be initiated?
Can abrupt discontinuation of estrogen therapy in a woman cause hypertension?
For a 55‑year‑old nonsmoking woman with hypertension who has hot flashes, sleep disruption, vaginal dryness, and dyspareunia, which of the following is the best first‑line treatment: (1) oral estrogen alone, (2) oral estrogen plus progesterone, (3) oral gabapentin, or (4) vaginal estrogen therapy?
Can discontinuation of testosterone replacement therapy cause hypertension?
Does progesterone affect blood pressure?
Given my mixed connective tissue disease-associated inflammatory myositis and G6PD deficiency, is my prognosis hopeless?
What is the differential diagnosis for a 70-year-old male with hypertension, hyperlipidemia, and type 2 diabetes mellitus who experiences episodes of lightheadedness, orthostatic symptoms, frequent falls, dizziness when climbing stairs, and headaches?
How should a patient with chronic obstructive pulmonary disease and chronic respiratory failure with hypoxia, currently taking ipratropium‑albuterol nebulizer, hyoscyamine (Levsin), nasal fluticasone propionate, and albuterol nebulizer, who presents with mild wheezing and feeling unwell, be evaluated and managed?
Can Effexor (venlafaxine) cause supraventricular tachycardia?
What is the recommended endoscopic therapy for bleeding esophageal varices in a patient with portal vein thrombosis?
What is the appropriate starting dose of a statin and what patient education should be given regarding side effects to monitor?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.